Figure 1From: A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade CLevel of Anti V3 antibodies in patient plasma (#254). 50% reciprocal binding titer of the plasma of the patient (#254) against consensus clade C and B V3 peptides. The results depict the average OD values of three independent experiments.Back to article page